A practical reference on GW501516: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-06-26. Anything still debated is marked as such rather than presented as settled.
Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.
Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
| Property | Value | Notes |
|---|---|---|
| IUPAC name | {4-[({4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl}methyl)sulfanyl]phenoxy}acetic acid | Systematic name for GW501516 |
| CAS Registry Number | 317318-70-0 | Unique identifier for the parent compound |
| Molecular formula | C21H18F3NO3S2 | Includes carbon, hydrogen, fluorine, nitrogen, oxygen, and sulfur |
| Molecular weight | 453.5 g/mol | Approximate value for the neutral form |
| Appearance | White to off-white powder | Typical description for purified laboratory material |
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
Laboratory handling focuses on identity, purity, and stability. Reference standards are typically stored cold and dry, protected from light, because solutions can degrade over time. Analytical checks may use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Impurities and related substances can be separated chromatographically and compared with a known standard. Because cardarine is not an approved drug, compendial monographs are absent, and laboratories often rely on in-house methods. Reported purity varies among unregulated products and should not be assumed from a label.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
In addition to being multi-varied and extraordinarily intense, these new dyes were notoriously unstable, rapidly fading and turning when exposed to sunlight, washing, and other chemical or physical agents. This led to new systems of categorization and study of colorants, which in turn lead to the synthesis of more color-fast modern colorants. Synthetic colors found themselves in not only dyes and paints but also inks and foodstuffs, permeating consumer culture.
== Function == SPINK functions as a competitive inhibitor of trypsin, which is a protease that can activate other proteases. It has been shown to prevent premature activation of pancreatic enzymes. Monitor peptide binds to intestinal epithelial cells and induces CCK-release, which enhances pancreatic secretion in the presence of nutritional protein in the duodenum. When all nutritional protein is digested, monitor peptide is bound by trypsin and subsequently degraded, resulting in decreasing CCK-release and a reduction of pancreatic secretion. Similar to CCK-releasing peptide (CCK-RP, homologous to DBI), it is trypsin sensitive and stimulates CCK release. It is possible that it also stimulates the growth of intestinal epithelial cells.
=== Genetic variations === An epigenetic mechanism (hypermethylation of CpG islands in the NET gene promoter region) that results in reduced expression of the noradrenaline (norepinephrine) transporter and consequently a phenotype of impaired neuronal reuptake of norepinephrine has been implicated in both postural orthostatic tachycardia syndrome and panic disorder. rs5569 is a variant of SLC6A2.
Sources: en.wikipedia.org
== Structures == Both classes of aminoacyl-tRNA synthetases are multidomain proteins. In a typical scenario, an aaRS consists of a catalytic domain (where both the above reactions take place) and an anticodon binding domain (which interacts mostly with the anticodon region of the tRNA). Transfer-RNAs for different amino acids differ not only in their anticodon but also at other points, giving them slightly different overall configurations. The aminoacyl-tRNA synthetases recognize the correct tRNAs primarily through their overall configuration, not just through their anticodon. In addition, some aaRSs have additional RNA binding domains and editing domains that cleave incorrectly paired aminoacyl-tRNA molecules. The catalytic domains of all the aaRSs of a given class are found to be homologous to one another, whereas class I and class II aaRSs are unrelated to one another. The class I aaRSs feature a cytidylyltransferase-like Rossmann fold seen in proteins like glycerol-3-phosphate cytidylyltransferase, nicotinamide nucleotide adenylyltransferase and archaeal FAD synthase, whereas the class II aaRSs have a unique fold related to biotin and lipoate ligases. The alpha helical anticodon binding domain of arginyl-, glycyl- and cysteinyl-tRNA synthetases is known as the DALR domain after characteristic conserved amino acids. Aminoacyl-tRNA synthetases have been kinetically studied, showing that Mg2+ ions play an active catalytic role and therefore aaRs have a degree of magnesium dependence.
== Medical applications – intravenous access and fluid delivery == The Hagen–Poiseuille equation is useful in determining the vascular resistance and hence flow rate of intravenous (IV) fluids that may be achieved using various sizes of peripheral and central cannulas. The equation states that flow rate is proportional to the radius to the fourth power, meaning that a small increase in the internal diameter of the cannula yields a significant increase in flow rate of IV fluids. The radius of IV cannulas is typically measured in "gauge", which is inversely proportional to the radius. Peripheral IV cannulas are typically available as (from large to small) 14G, 16G, 18G, 20G, 22G, 26G. As an example, assuming cannula lengths are equal, the flow of a 14G cannula is 1.73 times that of a 16G cannula, and 4.16 times that of a 20G cannula. It also states that flow is inversely proportional to length, meaning that longer lines have lower flow rates. This is important to remember as in an emergency, many clinicians favor shorter, larger catheters compared to longer, narrower catheters. While of less clinical importance, an increased change in pressure (∆p) — such as by pressurizing the bag of fluid, squeezing the bag, or hanging the bag higher (relative to the level of the cannula) — can be used to speed up flow rate. It is also useful to understand that viscous fluids will flow slower (e.g. in blood transfusion). Delivery of fluids such as antibiotics or analgesics by means of an elastomeric pump can also be understood in terms of a Poiseuille-flow model.
The polymerization cofactor profilin and the ATP·actin combine to form a profilin-ATP-actin complex that then binds to the end-tracking unit The cofactor and monomer are transferred to the barbed-end of an actin already clamped filament The tracking unit and cofactor dissociate from the adjacent protofilament, in a step that can be facilitated by ATP hydrolysis energy to modulate the affinity of the cofactor and/or the tracking unit for the filament; and this mechanoenzymatic cycle is then repeated, starting this time on the other sub-filament growth site. When operating with the benefit of ATP hydrolysis, AC motors generate per-filament forces of 8–9 pN, which is far greater than the per-filament limit of 1–2 pN for motors operating without ATP hydrolysis. The term actoclampin is generic and applies to all actin filament end-tracking molecular motors, irrespective of whether they are driven actively by an ATP-activated mechanism or passively. Some actoclampins (e.g., those involving Ena/VASP proteins, WASP, and N-WASP) apparently require Arp2/3-mediated filament initiation to form the actin polymerization nucleus that is then "loaded" onto the end-tracker before processive motility can commence. To generate a new filament, Arp2/3 requires a "mother" filament, monomeric ATP-actin, and an activating domain from Listeria ActA or the VCA region of N-WASP. The Arp2/3 complex binds to the side of the mother filament, forming a Y-shaped branch having a 70-degree angle with respect to the longitudinal axis of the mother filament.
Sources: en.wikipedia.org
Primary treatments: use physical methods such as flotation, screening, and sedimentation to remove oil and grease and other suspended solids. Secondary treatments: use biological and physicochemical means. Biological treatments use microorganisms to metabolise the organic polluting matter into energy and biomass. "These microorganisms can be aerobic or anaerobic. The most used aerobic processes are activated sludge system, aerated lagoons, trickling filters or bacterial beds and the rotating biological contractors. During anaerobic digestion, microorganisms break down organic matter without oxygen, producing biogas, mainly methane and carbon dioxide, and a nutrient-rich residue called digestate. The digestion of protein- and fat-rich fish waste can be slowed by the accumulation of ammonia and fatty acids. Mixing fish waste with other organic materials can improve process stability, although the results depend on the mixture and operating conditions. In the physicochemical treatments, also called coagulation-flocculation, a chemical substance is added to the effluent to reduce the surface charges responsible for particle repulsions in a colloidal suspension, thus reducing the forces that keep its particles apart. This reduction in charge causes flocculation (agglomeration) and particles of larger sizes are settled and clarified effluent is obtained. The sludge produced by primary and secondary treatments is further processed in digesting tanks through anaerobic processes or sprayed over land as a fertilizer.
While some strategies endorsed in the program, including needle-exchange programs and good samaritan laws, became mainstream in American drug policy, other approaches that were advocated at the conference, including safe injection sites, have yet to be widely endorsed in the United States. Nadelmann said at the time of the conference, "We could cut heroin overdoses in half if the information from this conference was widely disseminated."
The evolutionary adaptation from primary to secondary vascular tissues demonstrates how this monocot developed its tree-like form, combining water conservation through its dense crown with structural stability from its specialized stem growth. These features collectively enable the species to thrive in challenging high-altitude, arid conditions where few other trees can survive.
Sources: en.wikipedia.org
No. Major drug regulators have not approved GW501516 for treating any medical condition. Products sold as cardarine are typically unapproved research chemicals or supplements, so their contents and safety are not assured.
It is prohibited by the World Anti-Doping Agency as a hormone and metabolic modulator. Athletes who test positive for GW501516 can face sanctions, including suspensions and loss of results.
Cardarine is a common or trade-style name, while GW501516 is the research code for the same chemical entity. Some sources also use Endurobol or GSK-516. The names refer to the same compound, not distinct drugs.
Cardarine is an investigational synthetic compound that acts as a PPARδ agonist. It is also known as GW501516 and has been studied mainly in preclinical research. It is not an approved medicine.